TY - JOUR
T1 - Medication adherence in patients with ocular hypertension or glaucoma
AU - Robin, Alan L.
AU - Muir, Kelly W.
N1 - Funding Information:
The medical writing support was provided by Catherine DeBrosse and Natalia Zhukovskaya of Complete Healthcare Communications, LLC, North Wales, PA, and was funded by Novartis.
Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/9/3
Y1 - 2019/9/3
N2 - Introduction: Nonadherence to medication is a challenge to effective treatment of many chronic diseases, including glaucoma, and persists even with interventions aimed at improving adherence. The reported rates of nonadherence to topical glaucoma medication vary widely from 16% to 67%, and it is estimated that less than a third of patients remained on their initial therapy after 12 months. Nonadherence can lead to disease progression and increased economic burden. Areas covered: This review examines factors that contribute to nonadherence in patients with glaucoma, including the severity of the disease, complexity of treatment, lack of knowledge in patients, poor communications between physician and patient, difficulty with self-administration of drops, side-effects, and medication costs. We discuss the unique challenges in identifying nonadherence in glaucoma patients and investigate the current approaches to improving adherence. Expert opinion: Strategies for improving adherence should combine new treatment methods with enhanced patient education. New pharmaceuticals may comprise multiple medications in a single bottle, making dosing regimens simpler. Novel drug delivery systems are in development, such as injectable products and implants releasing IOP-lowering medication without the need for self-administration. A comprehensive approach involving these new methods and more effective patient-physician communication may lead to improved adherence.
AB - Introduction: Nonadherence to medication is a challenge to effective treatment of many chronic diseases, including glaucoma, and persists even with interventions aimed at improving adherence. The reported rates of nonadherence to topical glaucoma medication vary widely from 16% to 67%, and it is estimated that less than a third of patients remained on their initial therapy after 12 months. Nonadherence can lead to disease progression and increased economic burden. Areas covered: This review examines factors that contribute to nonadherence in patients with glaucoma, including the severity of the disease, complexity of treatment, lack of knowledge in patients, poor communications between physician and patient, difficulty with self-administration of drops, side-effects, and medication costs. We discuss the unique challenges in identifying nonadherence in glaucoma patients and investigate the current approaches to improving adherence. Expert opinion: Strategies for improving adherence should combine new treatment methods with enhanced patient education. New pharmaceuticals may comprise multiple medications in a single bottle, making dosing regimens simpler. Novel drug delivery systems are in development, such as injectable products and implants releasing IOP-lowering medication without the need for self-administration. A comprehensive approach involving these new methods and more effective patient-physician communication may lead to improved adherence.
KW - Adherence
KW - glaucoma
KW - intraocular pressure
KW - medication persistence
KW - patient education
UR - http://www.scopus.com/inward/record.url?scp=85073612361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073612361&partnerID=8YFLogxK
U2 - 10.1080/17469899.2019.1635456
DO - 10.1080/17469899.2019.1635456
M3 - Review article
AN - SCOPUS:85073612361
VL - 14
SP - 199
EP - 210
JO - Expert Review of Ophthalmology
JF - Expert Review of Ophthalmology
SN - 1746-9899
IS - 4-5
ER -